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Abstract: Cortical theta burst stimulation (TBS) structured as intermittent (iTBS) and continuous (cTBS)
could prevent the progression of the experimental autoimmune encephalomyelitis (EAE). The interplay
of brain antioxidant defense systems against free radicals (FRs) overproduction induced by EAE,
as well as during iTBS or cTBS, have not been entirely investigated. This study aimed to examine
whether oxidative-nitrogen stress (ONS) is one of the underlying pathophysiological mechanisms of
EAE, which may be changed in terms of health improvement by iTBS or cTBS. Dark Agouti strain
female rats were tested for the effects of EAE and TBS. The rats were randomly divided into the control
group, rats specifically immunized for EAE and nonspecifically immuno-stimulated with Complete
Freund’s adjuvant. TBS or sham TBS was applied to EAE rats from 14th–24th post-immunization
day. Superoxide dismutase activity, levels of superoxide anion (O2•–), lipid peroxidation, glutathione
(GSH), nicotinamide adenine dinucleotide phosphate (NADPH), and thioredoxin reductase (TrxR)
activity were analyzed in rat spinal cords homogenates. The severity of EAE clinical coincided with
the climax of ONS. The most critical result refers to TrxR, which immensely responded against the
applied stressors of the central nervous system (CNS), including immunization and TBS. We found
that the compensatory neuroprotective role of TrxR upregulation is a positive feedback mechanism
that reduces the harmfulness of ONS. iTBS and cTBS both modulate the biochemical environment
against ONS at a distance from the area of stimulation, alleviating symptoms of EAE. The results of
our study increase the understanding of FRs’ interplay and the role of Trx/TrxR in ONS-associated
neuroinflammatory diseases, such as EAE. Also, our results might help the development of new ideas
for designing more effective medical treatment, combining neuropsychological with noninvasive
neurostimulation–neuromodulation techniques to patients living with MS.
Keywords: thioredoxin reductase; oxidative stress; nitrosative stress; theta burst stimulation;
experimental autoimmune encephalomyelitis; rats
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1. Introduction
Experimental autoimmune encephalomyelitis (EAE) is an animal model of relapsing-remitting
multiple sclerosis (MS). Repeated neuroinflammatory attacks induce demyelination,
neuronal damage/loss, reactive gliosis, the formation of sclerotic plaques, and aggravate
remyelination. Those processes are oxidative-nitrosative stress (ONS) associated [1].
The mitochondrial respiratory chain is a primary source of reactive oxygen species (ROS)
in physiological conditions [2]. The overproduction of ROS and reactive nitrogen species (RNS)
mainly arise from activated glial and T cells and overwhelms the antioxidant capacity in EAE
neuroinflammation. Enzymatically catalyzed redox reactions deplete the donors of reducing
equivalents, such as nicotinamide adenine dinucleotide phosphate (NAD(P)H) and glutathione
(GSH). The central antioxidant enzymes that catalyze ROS sequestration are superoxide dismutase
(SOD) and catalase. At the same time, glutathione reductase (GR), glutathione peroxidase,
and glutathione-S-transferase are crucial enzymes of the glutathione cycle. Thioredoxin (Trx) and
thioredoxin reductase (TrxR) make up the thioredoxin system [3]. The engagement and role of the
Trx/TrxR system have not been clarified entirely [4,5]. It is known that Trx as an endogenous antioxidant,
reduces disulfide forms of proteins. Flavo- and selenoprotein TrxR regenerates the oxidized form of
Trx by utilizing cofactor NADPH. As GSH, Trx is likewise an astroglia-derived neuro-protectant [6–8].
The inability of the antioxidant defense system to counteract ROS overproduction in the central
nervous system (CNS) is coupled with a lack of energy, seen in all ONS-associated diseases, including MS.
Low adenosine three phosphates production (ATP), a vital source of energy, is the consequence of
the slaughtered function of mitochondria, as seen in MS [9]. Feedback mechanisms by which
glucose-6-phosphate may be utilized in glycolysis to compensate for the lack of energy results in ATP
and NADH production used to store energy in the form of glycogen, or used by the pentose phosphate
pathway compensates energy loss and keep the viability of cells [10]. Oxidative stress hinders the
myelination of axons mediated by oligodendrocytes and oligodendrocyte progenitor cells (OPCs)
differentiation into oligodendrocytes [11].
The repetitive transcranial stimulation arouses remyelination and fosters the expression of
neurotrophic factors that are of significant importance for neuro-regeneration in EAE animals [12].
In the cerebral cortex, it may promote neuronal activities in remote zones of the spinal cord connected
to the primary motor pathway—corticospinal tract. Additionally, neuronal activity is found to be
essential for OPCs differentiation into oligodendrocytes in the CNS [11,13].
Structured patterns of repetitive transcranial stimulation, such as theta burst stimulation
(TBS), modulate motor cortical excitability. Intermittent TBS (iTBS) provokes an early stage of
long-term potentiation, while continuous TBS (cTBS) induces an early stage of long-term depression.
Cortical neuronal activities (excitation and inhibition) are associated with neuronal plasticity, support,
and remyelination of the affected neural tissue in the lumbar spinal cord [14]. The precise underlying
mechanisms of iTBS or cTBS have not revealed yet.
When considering the above data, we aimed to evaluate redox homeostasis in EAE and during
iTBS and cTBS in the spinal cord of EAE in rats.
2. Materials and Methods
2.1. Animals and Experimental Procedure
The experiment was conducted in female Dark Agouti (DA) rats, weighed 150–200 g, and aged
10–14 weeks [15]. The animals (six per cage) were housed in polyethylene cages under standardized
housing conditions (ambient temperature of 23 ± 2 ◦C, the relative humidity of 55 ± 3%, a light/dark
cycle of 13/11 h). The access to laboratory food and water was ad libitum, and for welfare assistance to
animals with developed EAE, food, and water were bottom-positioned. The rats were habituated to
the ambient and laboratory staff five days before the experimental procedure. The experiment lasted
25 days. The TBS started from 14th post-immunization day (dpi) in EAE rats and lasted ten days.
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Rats were intraperitoneally anesthetized with sodium pentobarbital and decapitated after 24 h of the
last treatment [16].
This EAE animal study is a part of the more significant EAE project, approved by the Ethical
Community of the Military Medical Academy (Belgrade, Serbia) (license no. 323-07-00622/2017-05),
which followed the principles of the governmental policy of Official Gazette Republic of Serbia
(No. 14/2009) and Directive 2010/63/EU.
The immunization of rats for EAE was performed by subcutaneous injection of 0.1 mL of rat
spinal cord homogenate (50% w/v in saline) that was suspended in Complete Freund’s Adjuvant (CFA),
containing 1 mg/mL Mycobacterium tuberculosis (CFA; Sigma, St. Louis, MO, USA) in the right hind rat
footpad. The rats were previously anesthetized intraperitoneally with sodium pentobarbital 45 mg/kg
body weight (Trittay, Germany) [16].
Theta burst stimulation by MagStim Rapid2 device with a 25 mm figure-of-eight coil (The MagStim
Company, Whitland, Dyfed, UK) was manually performed. The coil was positioned over bregma in
direct physical contact with the animal head [14]. The iTBS block consisted of 600 pulses during 192 s.
Twenty trains of 10 bursts with three pulses at a frequency of 50 Hz, repeated at 5 Hz, with 10 s pauses
between trains were applied [17,18]. The cTBS consisted of 600 pulses set in a single train of bursts
during 40 s, repeated at 5 Hz. The applied intensity corresponded to the 30% of maximal strength of
TBS, which was merely under a motor threshold of rats, evaluated as a visible contraction of upper
limbs without any other apparent distress (Scheme 1). The rats were monitored daily and clinically
scored for EAE neurological signs.
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(sham-treated EAE rats). 
2.2. Clinical Evaluation 
Scheme 1. Theta burst stimulation of rats. Rats (n = 54) were randomized into two categories,
non-experimental autoimmune encephalomyelitis (EAE), and EAE groups, besides the C-control group.
Nine groups (n = 6/group) in total. Non-EAE groups: Complete Freund’s Adjuvant (CFA)—rats treated
with Complete Freund’s Adjuvant, Intermittent theta burst stimulation (iTBS), and continuous
TBS (cTBS) groups—rats subjected to iTBS and cTBS.—EAE groups: EAE-rats with experimental
autoimmune encephalo yelitis, EAE + iTBS, and E E + cTBS groups—EAE rats subjected to iTBS and
cTBS, and EAE + iTBSsh and EAE + cTBSsh—EAE ats subjected to iTBS’s and cTBS’s oise artifact
(sham-treated EAE rats).
2.2. Clinical Evaluation
The ouble-blind approac was applied for the rats’ daily observation and scoring f EAE signs,
up to 24 dpi. The clinical symptoms and signs were ranged from 0 to 5: 0—no oddity; 0.5—fairly lose
tail tone and inability to rotate the posterior side of the tail; 1—depressed tail tonus; 1.5—moderately
unsteady walk and reduced ability to straight-up or their combination; 2—weakness of hind limbs;
2.5—incomplete hind limb paralysis; 3—complete hind limb paralysis; 3.5—complete paralysis of
posterior and weakness of the front legs; 4—quadriplegia with breathing effort; and, 5—moribund or
death [19].
The following descriptors (presented as Mean ± STDEV) for the severity of EAE clinical symptoms
and monitoring of the iTBS or cTBS effects were considered: incidence (proportion of rats with clinical
score ≥0.5 per group); daily clinical score (rating of clinical symptoms per rat per day); maximal clinical
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severity score (duration of the most severe clinical symptoms (days)); EAE onset (the appearance of
the early clinical signs (day)); duration of paralysis (period after the EAE onset, when rats had a score
≥2.5 (days)); and, mortality rate.
2.3. Tissue Homogenates and Biochemical Analyses
The spinal cords were dissected, and lumbar region slices were transferred separately into saline
solution (0.9% w/v). A crude mitochondrial fraction was prepared, as follows: aliquots (1 mL) were
homogenized (homogenizer—Tehtnica Zelezniki Manufacturing, Zalezniki, Slovenia) twice using
Teflon pestle at 800 rpm (1000× g) for 15 min. at 4 ◦C, and centrifuged at 2500× g for 30 min, at 4 ◦C.
The subcellular membranes pellet was solubilized in 1.5 mL of deionized water, by constant mixing
with Pasteur pipette, for 1 h. The mixture was then centrifuged at 2000× g for 15 min., at 4 ◦C,
and supernatant (a crude mitochondrial fraction) was used for analysis [20].
Nitrite and nitrate concentration (NO2+NO3) was spectrophotometrically determined at 492 nm,
using the colorimetric Griess method [21].
Lipid peroxidation was spectrophotometrically determined by using the thiobarbituric acid
reactive species (TBARS) assay, as described by Girotti et al. The results are expressed as nmol of
malondialdehyde (MDA) per milligram of proteins (nmol MDA/mg protein) [22].
Superoxide anion (O2•−) was spectrophotometrically determined at 550 nm. The principle of the
method relates to the reduction of nitroblue-tetrazolium (Merck, Darmstadt, Germany) in the alkaline,
nitrogen saturated medium [23].
Superoxide dismutase (EC 1.15.1.1.; SOD) activity was expressed as the degree of inhibition of
epinephrine auto-oxidation by SOD, in the presence of O2, in alkaline pH. It was spectrophotometrically
measured at 480 nm [24].
Total sulfhydryl groups (SH) were spectrophotometrically measured at 412 nm by Elman’s
method [25].
Total GSH was spectrophotometrically measured at 412 nm, for 6 min.,
by 5,5-dithiobis-2-nitrobenzoic acid (DTNB)—oxidized glutathione (GSSG) recyclable method.
The level of produced 5-thio-2-nitrobenzoic acid (TNB) was proportional to the total GSH
concentration [26]. The content of total GSH was expressed as nmol/mg protein.
Thioredoxin reductase activity was spectrophotometrically measured at 412 nm with a
commercially available Assay kit (Abcam; ab83463). The principle of the method refers to the
reduction of 5,5′-dithiobis(2-nitrobenzoic) acid (DTNB) into yellow-colored 5-thio-2-nitrobenzoic acid
(TNB), catalyzed by thioredoxin reductase that utilizes NADPH. The results are expressed as mU/mg
proteins (one unit of thioredoxin reductase activity equals the formation of 1,0 µmol of TNB per minute
at 25 ◦C) [27].
The reduced form of NADPH was spectrophotometrically determined using commercial NADPH
Assay Kit at OD450nm (Abcam, Cambridge, UK) [28].
Total proteins were determined by the Lowry method [29].
2.4. Statistical Analysis
One-way ANOVA and Bonferroni’s post hoc multiple tests were used (software GraphPad Prism,
version 5.03) for statistical data analysis. The values are presented as means ± SD. The level of
confidence referred to p < 0.05.
3. Results
3.1. Clinical Observation
The onset of EAE symptoms was established at 10.5± 0,23 dpi in all immunized rats (100% incidence
of the EAE onset). No lethality occurs in any of the experimental groups. The same pattern,
addressing the onset and the duration of EAE clinical manifestations, was recognized within the non-
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and TBS treated EAE groups. Non-TBS treated groups refer to EAE and sham i/cTBS treated EAE
groups, and TBS treated EAE groups refer to i/cTBS treated EAE groups. The duration of limb paralysis
(p < 0.05) and severity of EAE symptoms were lower in TBS treated EAE rats than in EAE rats (Table 1).
Table 1. Alleviation of EAE clinical symptoms by iTBS and cTBS in rats.
Experimental
Groups
Maximal Clinical Severity Score Paralysis Body Mass Loss and Gained
Started (dpi) Lasted (Days) Started (dpi) Lasted (Days) Min. Weight (%) Gained Weight (%)
EAE
EAE+i/cTBSsh 11.8 3.08 ± 0.97 12
~3.5
~2.5 ~70 (14th dpi) ~96 (20–24th dpi)
EAE+i/cTBS 11.5 2.79 ± 0.76 11.8 ~1.7 a ~81 (15th dpi) ~90 (20–24th dpi)
a p < 0.05; Legend: EAE—rats with experimental autoimmune encephalomyelitis; EAE + i/cTBS [EAE + iTBS,
and EAE + cTBS groups—EAE rats subjected to iTBS and cTBS]; EAE + i/cTBSsh [EAE + iTBSsh and
EAE + cTBSsh—EAE rats subjected to iTBS’s and cTBS’s noise artifact (sham-treated EAE rats)].
The progress of EAE (development and withdrawal of severe clinical signs) overlapped with body
mass loss and its gaining back (Figure 1).
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treated EAE rats (reduction for 30% and 19%; and, achieved 96% vs. 90% of the initial weight, 
Figure 1. The effect of EAE, i/cTBS, and sham i/cTBS on the rat body mass. The average values of body
mass changes per gr up were presente linearly and are expressed as a percentage of initial body weight.
Legend: EAE—rats with exp rimental autoimmune enc phalomyelitis; EAE + i/cTBS [EAE + iTBS,
and EAE + cTBS groups—EAE rats subjected to iTBS and cTBS]; EAE + i/cTBSsh [EAE + iTBSsh and
EAE + cTBSsh—EAE rats subjected to iTBS’s and cTBS’s noise artifact (sham-treated EAE rats)].
The drop in the body mass and gaining back was more intense in non-TBS treated than in
TBS treated EAE rats (reduction for 30% and 19%; and, achieved 96% vs. 90% of the initi l weight,
respectively) as compared to 10th dpi, when EAE o set happened. The body mass loss co ncided with
paralysis (Table 1, Figure 1).
Clinical symptoms, including motoric/walking possibilities and developed inabilities,
were observed daily and scored in EAE, TBS-, and sham-TBS- treated EAE rats. The totals of
daily clinical scores were summarized for days before (0–13th dpi) and during (14–24th dpi) the
applied TBS or sham TBS to EAE rats (Figure 2). The summarized clinical scores for 14–24th dpi were
significantly lower in TBS treated EAE rats when compared to EAE rats (p < 0.05), whereas cTBS
achieved better health effects.
3.2. Oxidative Stress Biochemical Analyses
The concentrations of NO2+NO3 increased in the TBS-untreated groups (EAE and EAE + iTBSsh
and EAE + cTBSsh) (p < 0.05) compared to both iTBS and cTBS-treated EAE groups, which remained
equal to the control values (Figure 3a).
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rats, and after iTBS/cTBS: (a) nitrite and nitrate (NO2+NO3; nmol/mg proteins); (b) lipid peroxidation
(TBARS; µmol/mg proteins—corresponds to malondialdehyde (MDA); (c) superoxide anion radical
(O2−; nmol/min/mg proteins); (d) superoxide dismutase (SOD; U/mg proteins). Values are presented as
means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 statistically significant difference compared to control,
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The concentrations of TBARS increased with progress and peak of the disease (EAE14; p < 0.01),
but lately it decreased (EAE24; p < 0.01). Decreased TBARS values were documented in both
TBS-treated EAE groups (EAE + iTBS and EAE + cTBS) and TBS-untreated EAE groups (EAE + iTBSsh
and EAE + cTBSsh), when compared to EAE14 (p < 0.01) (Figure 3b).
In both of TBS-treated (EAE + iTBS, EAE + cTBS) and TBS-untreated EAE groups (EAE + iTBSsh,
EAE + cTBSsh), the production of O2− decreased, as compared to the peak of the disease (EAE14;
(p < 0.01). In this term, O2− elevated, when compared to controls (p < 0.001). Remarkable data
were depleted production of O2− in healthy animals treated with iTBS (p < 0.05) and cTBS (p < 0.01),
compared to controls (Figure 3c).
A significant drop of SOD activity was measured on the 10th day in EAE rats (EAE10; p < 0.001)
as compared to the controls, while afterward, it started to rise (EAE14/24, p < 0.01; compared to
EAE10). The activity of SOD also decreased in CFA treated animals (p < 0.001), cTBS-treated EAE
group (EAE + cTBS; p < 0.001) and in TBS-nontreated rats (EAE + iTBSsh and EAE + cTBSsh; p < 0.001).
Increased SOD activity occurred in EAE + iTBS rats, as compared to all EAE groups (EAE10, p < 0.001;
EAE14, p < 0.01; EAE24, p < 0.05) (Figure 3d).
The concentration of thiols (SH-containing compounds) declined with the disease progress (EAE14,
p < 0.05: compared to the controls). Elevated values of thiols were measured in both iTBS and cTBS
treated EAE compared to all EAE groups (EAE10/14/24 groups, p < 0.05) (Figure 4a).
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Figure 4. (a–d). Thiol-associated biochemistry and NADPH status in the rat spinal cord. Parameters of
thiol species-associated biochemistry in the spinal cord at 10, 14 and 24 dpi in EAE rats, and after
iTBS/cTBS: (a) total sulfhydryl groups (SH; µmol/mg proteins); (b) Glutathione (GSH; nmol/mg
proteins); (c) Thioredoxin reductase (TrxRs, mU/mg proteins); (d) Nicotinamide adenine dinucleotide
phosphate-reduced form (NADPH) (pmol NADPH/mg proteins). Values are presented as means ± SD.
* p < 0.05, ** p < 0.01, *** p < 0.001 statistically significant difference compared to control, ◦ p < 0.05,
◦◦◦ p < 0.001 compared to EAE10, • p < 0.05, ••• p < 0.001 compared to EAE14,  p < 0.05,  p < 0.001
as compared to EAE24.
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The GSH decreased in EAE10 and EAE14 groups compared to the controls (p < 0.05). The renewal
of GSH content happened on the 24th day (EAE24). The cTBS increased GSH in EAE rats (EAE + cTBS),
when compared to EAE24 (p < 0.05). Interestingly, iTBS increased GSH in healthy animals (p < 0.001)
(Figure 4b).
The activity of TrxR increased in all experimental groups [CFA (p < 0.05); EAE10,14,24 (p < 0.01);
EAE + i/cTBS (p < 0.01); EAE + i/cTBSsh (p < 0.01); i/cTBS (p < 0.01)] compared to controls. The activity
of TrxR decreased in TBS-untreated groups [(EAE + iTBSsh (p < 0.05) and EAE + cTBSsh (p < 0.05)] as
well as in EAE + cTBS rats (p < 0.05), as compared to EAE24 group (Figure 4c).
The depletion of NADPH occurred in the spinal cord of EAE 10/14/24, CFA group, and both sham
TBS-treated EAE rats, compared to the controls (all p < 0.05). The iTBS and cTBS increased NADPH
concentration back to control levels in treated EAE rats. Additionally, NADPH in EAE + iTBS rats was
higher from EAE10/14/24 groups (p < 0.05) (Figure 4d).
4. Discussion
Herein, we provided inclusive results on the status of ROS/RNS, reducing equivalents (NADPH
and thiol compounds, including GSH) and relevant antioxidant enzymes, such as SOD and TrxR in
rats immunized for EAE and during iTBS and cTBS. The peak of ONS coincided with the climax of
EAE clinical manifestation. Besides, we will discuss the experimental and clinical achievements of the
therapeutic protection in the pathogenesis of EAE, i.e., MS [30].
The close association of EAE pathology and ONS was confirmed by the overlapping of the peak of
EAE clinical score, achieved at 14 dpi and highpoint of ONS measured in the spinal cord of treated rats.
Among the measured ONS parameters, the focus fell on TrxR, which appears to be the most sensitive
parameter of ONS [31]. Additionally, we documented that TBS of EAE rats mitigated the ONS in
the spinal cord and improved clinical symptoms of EAE. The effect was realized, both at the site of
stimulation and in the zone of the spinal cord [32,33]. Contrary to the report on opposite modulation
directions of cortical excitability by cTBS and iTBS in EAE, we obtained almost similar outcomes by
both iTBS and cTBS, with somewhat more beneficial effects being accomplished by cTBS (Figure 2).
Underlying mechanisms of TBS to raise neuronal activity, adult neurogenesis, and remyelination
mediated by astrocytes and microglia/macrophages have not been fully elucidated. The lack
of pharmacological treatment effectiveness fortifies the exploitation of nonpharmacological and
noninvasive repetitive transcranial magnetic stimulation for cognitive rehabilitation in MS patients.
This neurostimulatory and neuromodulatory technique realize electromagnetic induction of an electric
field in the brain, with behavioral consequences and therapeutic potentials. Locally and remotely,
it affects neural functions, excitatory, or inhibitory [34].
In terms of nitrosative stress, our results showed that NOx levels were the highest in EAE rats,
while lately, applied TBS reduced it slightly (Figure 3a). Nitrogen monoxide regulates cerebral blood
flow and neuronal cell viability. As a weak oxidant, NO is incapable of inducing ONS, unlike its radical
form (NO·), which causes only modest BBB disruption, while in combination with other RNS elicits
severe BBB damage. Additionally, high levels of RNS in the brain participate in neurotoxicity [35].
Increased metabolism of NOx is the hallmark of glutamate turnover, i.e., excitotoxicity in EAE.
Glutamate-mediated excitotoxicity occurs via ionotropic glutamate receptors activation and increased
calcium (Ca2+) influx. Cells Ca2+ overload affects mitochondrial respiratory chain and ATP production,
which is an early occurrence in EAE lesions.
Additionally, macrophages and microglia influence metabolic and regenerative processes,
striping myelin and inducing matrix metalloproteinases that are involved in the vascular response
to oxidative insult [35]. The localization of mitochondria within axons is essential for maintaining
axonal integrity, demyelination, and remyelination [36]. The release of ROS from macrophages occurs
during phagocytosis (“oxidative burst”) of engulfed debris and toxic products from the surrounding
environment [37]. Oxidatively damaged neighbor health tissue, although not affected by inflammation,
can facilitate the infiltration of immune cells, which is the scenario recognized in an early stage of
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EAE [38]. Assumingly, that could be the explanation of the simultaneous occurring of EAE symptoms
severity and climax of ONS.
Antioxidant enzyme SOD converts O2•− into molecular oxygen and hydrogen peroxide,
by utilizing NAD(P)H. Reduced SOD activity, documented on 10 dpi, was followed with the reduced
elimination of O2•−, which resulted in its peak on 14 dpi, which coincided with the severity of lipid
peroxidation (expressed as TBARS) and the most severe clinical signs in EAE rats. However, the return
of SOD to normal on 14th dpi resulted in the consequent decrease of O2•− and TBARS to control
values (Figure 3b,c), according to the study of Thimm et al. (Figure 3c,d) [39]. Proapoptotic O2•−
emerges tumor necrosis factor-α (TNF-α) mediation in ONS in the cerebral vascular endothelium. It is
known that TNF-α has a pivotal role in various types of inflammatory brain diseases. Consequently,
the removal of O2•− reduces inflammation via the TNF-α pathway [35].
Reduced SOD activity along with NADPH in CFA, EAE, and sham-TBS treated EAE rats (Figure 3d)
indicate that both nonspecific immuno-stimulation (CFA-mediated) and specific (immunization for EAE)
deteriorated redox homeostasis in the direction of ONS [40]. The distinctive impact of iTBS and cTBS
on SOD activity was documented in EAE treated rats. Its activity increased under the iTBS, while cTBS
did not impose any effect. The nuclear factor (erythroid-derived-2)-like 2 factor (Nrf2) upregulates
antioxidative enzymes in nervous tissue. The Nrf2 path quenched in EAE; thus, we speculated that
iTBS supports the Nrf2 pathway that supports SOD activity [41]. Mitochondrial function is particularly
compromised by the excess of glutamate and pro-inflammatory mediators (proteases, inflammatory
cytokines, etc.). The oxidative damage of neuronal and glial cells, including OPCs, as well as recruited
T cells at the site of inflammation, could be a reason for matrix metalloproteinases production and
the blood-brain barrier disrupter. The dysregulation of the BBB is among the earliest cerebrovascular
abnormalities seen in MS brains. Deteriorated BBB integrity increases the permeability of cerebral
micro-vessels seen in many neurological inflammatory diseases [42].
The occurrences mentioned above coincided with a decrease of GSH, total sulfhydryl (-SH)
containing compunds (thiols), and NAD(P)H (Figure 4a,b,d). The changes in total SH-containing
compounds and GSH were similar (Figure 4a). It is well-known that -SH groups of cysteine in
GSH is responsible for its antioxidant and other physiological roles. As a strong nucleophile,
SH-groups are prone to oxidation, which was probably the reason for the reduced content of
thiols and GSH documented in EAE and EAE + iTBSsh or EAE + cTBSsh groups, as compared to
controls [43]. Thiols reduce an oxidative attack and preserves surrounding biomolecules from oxidative
damage. The functional impairment of SH-groups containing molecules could arise from metabolic
disorders but also long-lasting overstimulation of neurons in EAE. In excitotoxicity, an overload of
the glutamate-cysteine transporters blocks cysteine transport, affecting cysteine, which is the source
of SH-group in GSH, and other thiol-proteins [44]. The GSH cycle encompasses several antioxidant
enzymes that utilize GSH or NADPH as donors for reducing equivalents.
Nevertheless, if applied to EAE or health rats, both iTBS and cTBS return the thiols and GSH to the
level controls. Mitochondrial GSH is recognized to be a critical factor in antioxidant protection. Thus,
impairment of mitochondrial physiology may considerably ruin the GSH antioxidant capacity [45].
The antioxidant effect of thiols may be the primary underlying mechanism of ROS sequestration
during reactive astrogliosis treated with TBS, particularly by iTBS, which arrives more effective than
cTBS in preserving/restoring of the GSH reserves (documented in health rats) (Figure 4b). The use
of transcranial magnetic stimulation in human medicine has been increasing lately, although limited
evidence of its effect on glia in vivo is available nowadays [46].
Unlikely to the GSH antioxidant role, little is known regarding the physiological significance
of the Trx system in this capacity [5,47–49]. To our knowledge, the present study is the first in the
literature to address the role of the Trx/TrxR system relative to the GSH system in the response of the
brain to induce EAE in rats.
Down-regulated antioxidant enzymes, next to impaired mitochondrial GSH pool in EAE rats
(Figure 4b), imply that GSH may not be effective enough in coping with the ONS evoked by EAE [45].
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Contrary to the reduced ROS sequestrating system (herein represented by SOD) and GSH system,
we obtained a remarkable increase of TrxR in rats that were immunized for EAE (specific immunization),
CFS (nonspecific vaccination), and TBS-treated health rats (Figure 4c). The decreased level of total thiols
(Figure 4a) correlates with increased TrxR activity. By that, we confirmed the exceptional protection
role of TrxR against brain oxidant injury in rats and its outstanding sensitivity to the applied CNS
stressors, according to the Ruszkiewicz, J. and Jan Albrecht, J. study [45]. It appears that the increase of
TrxR activity accomplishes a neuroprotective role. That is the positive feedback mechanism against
ONS. We showed that upregulated TrxR compensated reduced GSH and SOD antioxidant role in EAE
rats, underlying its antioxidant role (Figure 4c). No differences in TrxR activity were documented
between EAE and healthy rats that were subjected to TBS. However, the capacity of the Trx/TrxR
system in different neurological diseases, such as EAE or during TBS, is not clarified yet. Thioredoxin
reductase imposes additional activities, besides the reduction of Trxs. It recycles ascorbate and imposes
another biological role in cell growth and transformation. However, increased brain Trx/TrxR role was
seen in hyperoxia in newborn rats and ischemia induced by transient middle cerebral artery occlusion
in adult mice, and in Alzheimer’s disease-affected brain [50–52]. The Trx/TrxR system accomplishes its
neuroprotective antioxidant role in the brain. It appears that the feedback mechanism of the Trx/TrxR
system supports the overcoming of the ONS-associated astrogliosis in EAE [12,53,54].
The decrease of NADPH in EAE rats was expected, due to its cofactor role in numerous enzymatic
oxidoreductive reactions, including GSH turnover by GR, reduction of Trx; and, other SH-compounds,
prone to oxidation (Figure 4d) [55]. The obtained result confirmed the increased utilization of NADPH
during OS and NS in EAE rats. As a cofactor in lipid and cholesterol synthesis and fatty acid
chain elongation, NAD(P)H is vital for neuronal tissue maintenance [56]. The consumption of GSH
and NAD(P)H in enzymatic reactions of FRs’ sequestrations entails the involvement of the pentose
phosphate pathway [57]. The recovery of NADPH and total thiols and glutathione under the iTBS
or cTBS promotes better metabolic achievement in EAE. No statistical significance of TrxR activity
between EAE or healthy rats subjected to TBS was obtained.
The maintenance of redox homeostasis and energy is a predominant target for EAE treatment.
The peak of EAE clinical symptoms positively correlated with the climax of ONS, including the
depletion of donors of reducing equivalents (NADPH and total thiols, including GSH), fall of SOD
activity, but the rise of TrxR activity. We recognized the upregulation of TrxR as a feedback mechanism
against red-ox balance perturbation in the brain and spinal cord of rats induced by stressors, such as
specific immunization for EAE, nonspecific immunization with CFS, and TBS as well.
A similar effect of TBS on TrxR activity was achieved in EAE and healthy rats. That is difficult
to explain because of the lack of knowledge addressing the Trx/TrxR system role in neurological
inflammatory diseases. iTBS and cTBS both modulate the biochemical environment against spinal
cord ONS and alleviate symptoms of EAE. Both TBSs shifted neuronal antioxidative defense towards
a more reductive state to improve physiological resilience to ONS by modulating the biochemical
environment in EAE at a distance from the area of stimulation. iTBS and cTBS both modulate the
biochemical environment against ONS at a distance from the area of stimulation, alleviating symptoms
of EAE.
This animal study significantly increases our understanding of FRs’ interplay and the role of
Trx/TrxR in ONS-associated neuroinflammatory diseases, such as EAE. For now, the antioxidant-based
therapies and management of neurodegenerative diseases in clinical and experimental settings have
identified antioxidant based therapies to be largely ineffective [58].
The results of our study might help the development of new ideas for designing
more effective medical treatment, combining neuropsychological with noninvasive
neurostimulation—neuromodulation techniques for patients living with MS [34].
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Abbreviations
CFA Complete Freund’s Adjuvant
CNS central nervous system
cTBS continuous theta burst stimulation
cTBSsh sham stimulated EAE rats, exposed to the sound artifacts of cTBS
dpi postimmunization days
EAE experimental autoimmune encephalomyelitis
iTBS intermittent theta burst stimulation
iTBSsh sham stimulated EAE rats, exposed to the sound artifacts of iTBS
MS multiple sclerosis
TBS theta burst stimulation
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